Biocon Limited has informed the Exchange about Company Statement
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's subsidiary Biocon Biologics has launched Nepexto®, a biosimilar of the anti-inflammatory drug Enbrel® (Etanercept), in Australia. The product will be promoted by local partner Generic Health to expand patient access. Nepexto® is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The drug already has EU marketing approval since 2020 and has been adopted widely across Europe. This launch is part of Biocon Biologics' strategy to expand its immunology portfolio into new global markets following its 2022 acquisition and integration of the biosimilars business.
This is a positive market-expansion milestone that opens a new revenue stream in Australia's pharmaceutical market, though no financial figures were disclosed. For shareholders, it signals continued global growth of the biosimilars franchise but is unlikely to move the stock significantly on its own.